MacroGenics, Inc.
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof

Last updated:

Abstract:

The present invention is directed to sequence-optimized CD123.times.CD3 bi-specific monovalent diabodies that are capable of simultaneous binding to CD123 and CD3, and to the uses of such diabodies in the treatment of hematologic malignancies.

Status:
Grant
Type:

Utility

Filling date:

12 Oct 2017

Issue date:

29 Sep 2020